Combination chemotherapy of solid tumors: an American-Italian collaboration: a celebration of the work of Gianni Bonadonna.

This article highlights the important collaboration between the U.S. NCI in Bethesda, Maryland and the Istituto Tumori in Milan, Italy that had a major impact on the development of curative regimens for breast cancer, Hodgkin's disease and diffuse large B cell lymphoma.

Gianni Bonadonna: A Personal Remembrance.

Gianni Bonadonna (1934–2015) is fondly remembered. His contributions to the field of oncology are highlighted, including a clinical trial to determine the effects of postoperative combination chemotherapy to prevent relapse of breast cancer, which led to a revolutionary treatment approach using various active agents, and a salvage regimen for the treatment of Hodgkin lymphoma.

Clinical cancer research: the past, present and the future.

In the past decade, we have witnessed unprecedented changes and some remarkable advances that have enabled true personalized medicine. Nevertheless, many challenges in clinical cancer research remain and need to be overcome if we are to witness similar progress in the next decade. Such hurdles include, but are not limited to, clinical development and testing of multiple agents in combination, design of clinical trials to best accommodate the ever increasing knowledge of heterogeneity of the disease, regulatory challenges relating to drug development and trial design, and funding for basic research.

Hematology in 2010: New therapies and standard of care in oncology.

2010 was not a year of survival breakthroughs in hematologic malignancies. However, in Hodgkin's disease and multiple myeloma new therapies emerged as the standard of care and nilotinib may be considered the treatment choice for newly diagnosed chronic myeloid leukemia.